A meta-analysis of salicylates for type 2 diabetes mellitus

Abstract

The aim of this study was to assess the effects and safety of salicylates on type 2 diabetes mellitus (T2DM). We searched six databases (Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CBM, CNKI and VIP) for all randomized controlled trials (RCTs) and self-control studies which investigated the effects of salicylates on T2DM. We included 34 RCTs and 17 self-control studies involving 13 464 patients with T2DM. It was demonstrated that salicylates had obvious effects on several parameters for patients with T2DM. (1) Any dose of salicylates could significantly reduce HbA1c level [mean difference (MD) −0.39%; 95% CI −0.47 to −0.32] in RCTs, but only high doses of salicylates (≥3000 mg/day) could effectively reduce fasting plasma glucose (FPG) level [standardized mean difference (SMD) −1.05; 95% CI −1.47 to −0.62] for patients with T2DM in both RCTs and self-control studies. Furthermore, high doses of salicylates could also increase plasma fasting insulin level (MD 12.20 mU/L; 95% CI 3.33 to 21.07); (2) In both RCTs and self-control studies, high doses of salicylates could significantly reduce plasma triglycerides concentration. The results for RCTs were MD −0.44 mmol/L, 95% CI −0.71 to −0.18, and those for self-control studies were 227±29 mg/dL (pre-treatment) and 117±8 mg/dL (post-treatment) (P=0.009); (3) All trials which reported cardiovascular events were RCTs using low doses (<1000 mg/day) of salicylates, and it was revealed that aspirin could significantly reduce the risk of myocardial infarction (OR 0.73; 95% CI 0.57 to 0.92); (4) Two RCTs and two self-control studies with ≥3000 mg/day salicylates reported adverse effects, and the overall effects were mild, and tinnitus occurred most frequently. No evidence of gastrointestinal bleeding was found in all these studies. In conclusion, from our systematic review, the anti-diabetic effect of salicylates is in a dose-dependent manner. High doses of salicylates may have beneficial effects on reducing FPG, HbA1c level and increasing fasting insulin concentration, and may also have some positive effects on lipidemia and inflammation-associated parameters for patients with T2DM, without serious adverse effects.

Keywords

salicylates / type 2 diabetes mellitus / meta-analysis

References

[1] CampbellR.K.. Type 2 diabetes: Where we are today: An overview of disease burden, current treatments, and treatment strategies. J Am Pharm Assoc, 2009, 49(suppl1): s3-s9

[2] RumoreM.M., KimK.S.. Potential role of salicylates in type 2 diabetes. Ann Pharmacother, 2010, 44(7–8): 1207-1221

[3] PignoneM., AlbertsM.J., ColwellJ.A., et al.. Aspirin for primary prevention of cardiovascular events in people with diabetes. J Am Coll Cardiol, 2010, 55(25): 2878-2886

[4] American Diabetes Association.. Aspirin therapy in diabetes. Diabetes Care, 2004, 27(suppl1): s72-s73

[5] GoldfineA.B., SilverR., AldhahiW., et al.. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci, 2008, 1(1): 36-43

[6] McCartyM.F.. Salsalate may have broad utility in the prevention and treatment of vascular disorders and the metabolic syndrome. Med Hypotheses, 2010, 75(3): 276-281

[7] FearnleyG.R., VincentC.T., ChakrabartiR.. Reduction of blood fibrinolytic activity in diabetes mellitus by insulin. Lancet, 1959, 2(7111): 1067

[8] OgastonD., McAndrewG.M.. Fibrinolysis in obesity. Lancet, 1964, 2(7371): 1205-1207

[9] GraceC.S., GoldrickR.B.. Fibrinolysis and body build. Interrelationships between blood fibrinolysis, body composition and parameters of lipid and carbohydrate metabolism. J Atheroscler Res, 1968, 8(4): 705-719

[10] HotamisligilG.S., ShargillN.S., SpiegelmanB.M.. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science, 1993, 259(5091): 87-91

[11] FeinsteinR., KanetyH., PapaM.Z., et al.. Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. J Biol Chem, 1993, 268(35): 26 055-26 058

[12] HotamisligilG.S., SpiegelmanB.M.. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes, 1994, 43(11): 1271-1278

[13] ShoelsonS.E., LEEJ., GoldfineA.B.. Inflammation and insulin resistance. J Clin Invest, 2006, 116(7): 1793-1801

[14] EbsteinW.Invited comment on W. Ebstein. On the therapy of diabetes mellitus, in particular on the application of sodium salicylate. J Mol Med, 2002, 80(10): 618-619

[15] WilliamsonR.T.. On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J, 1901, 1(2100): 760-762

[16] ReidJ., MacdougallA.I., AndrewsM.M.. Aspirin and diabetes mellitus. Br Med J, 1957, 2(5053): 1071-1074

[17] HechtA., GoldnerM.G.. Reappraisal of the hypoglycemic action of acetylsalicylate. Metabolism, 1959, 8(4Pt1): 418-428

[18] GilgoreS.G.. The influence of salicylate on hyperglycemia. Diabetes, 1960, 9(5): 392-393

[19] GoldfineA.B., FonsecaV., JablonskiK.A., et al.. The effects of salsalate on glycemic control in patients with type 2 diabetes. Ann Intern Med, 2010, 152(6): 346-357

[20] FleischmanA., BernierR., ShoelsonS.E.. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care, 2008, 31(2): 289-294

[21] KoskaJ., OrtegaE., BuntJ.C., et al.. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomized double-blind placebo-controlled study. Diabetologia, 2008, 52(3): 385-393

[22] PierceG.L., LesniewskiL.A., LawsonB.R., et al.. Nuclear factor-{kappa}B activation contributes to vascular endothelial dysfunction via oxidative stress in overweight/ obese middle-aged and older humans. Circulation, 2009, 119(9): 1284-1292

[23] HigginsJ.P., AltmanD.G.. HigginsJ.P., GreenS.. Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions, 20085.0.2 ed.England, John Wiley & Sons Ltd, 206

[24] JadadA.R., MooreR.A., CarrollD., et al.. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials, 1996, 17(1): 1-12

[25] DeeksJ.J., HigginsJ.P., AltmanD.G.. HigginsJ.P., GreenS.. Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions, 20085.0.2 edEngland, John Wiley & Sons Ltd, 206

[26] HigginsJ.P., DeeksJ.J., AltmanD.G.. HigginsJ.P., GreenS.. Special topics in statis tics. Cochrane Handbook for Systematic Reviews of Interventions, 20085.0.2 ed.England, John Wiley & Sons Ltd, 206

[27] BelchJ., MacCuishA., CampbellI., et al.. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomized controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. Br Med J, 2008, 337: a1840

[28] CamargoE.G., WeinertL.S., LavinskyJ., et al.. The effect of aspirin on the antiproteinuric properties of enalapril in microalbuminuric type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. Diabetes Care, 2007, 30(7): e66

[29] CamargoE.G., PedriniR.O., GrossJ.L., et al.. Lack of interference of aspirin in HbA1c measured by ion-exchange HPLC in type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. Clin Chim Acta, 2008, 391(1–2): 120-122

[30] ChewE.Y., WilliamsG.A., BurtonT.C., et al.. Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16. Arch Ophthalmol, 1992, 110(3): 339-342

[31] ChewE.Y., KleinM.L., MurphyR.P., et al.. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Arch Ophthalmol, 1995, 113(3): 52-55

[32] ContrerasI., ReiserK.M., MartinezN., et al.. Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM. Diabetes Care, 1997, 20(5): 832-835

[33] GaedeP., HansenH.P., ParvingH.H., et al.. Impact of low-dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate. Nephrol Dial Transplant, 2003, 18(3): 539-542

[34] HanssonL., ZanchettiA., CarruthersS.G., et al.. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet, 1998, 351(9118): 1755-1762

[35] HovensM.M., SnoepJ.D., GroeneveldY., et al.. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial. Diabetes Obes Metab, 2008, 10(8): 668-674

[36] KhajehdehiP., RoozbehJ., MostafaviH.. A comparative randomized and placebo-controlled short-term trial of aspirin and dipyridamole for overt type-2 diabetic nephropathy. Scand J Urol Nephrol, 2002, 36(2): 145-148

[37] KodamaM., YamasakiY., SakamotoK., et al.. Antiplatelet drugs attenuate progression of carotid intima-media thickness in subjects with type 2 diabetes. Thromb Res, 2000, 97(4): 239-245

[38] MorkN.L., RobertsonR.P.. Effects of nonsteroidal antiinflammatory drugs in conventional dosage on glucose homeostasis in patients with diabetes. West J Med, 1983, 139(1): 46-49

[39] Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. The DAMAD Study Group. Diabetes, 1989,38(4):491–498

[40] Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. . N Engl J Med, 1989, 321(3): 129-135

[41] Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. . Ophthalmology, 1991, 98(5 Suppl): 757-765

[42] Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA, 1992,268(10):1292–1300

[43] OgawaH., NakayamaM., MorimotoT., et al.. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008, 300(18): 2134-2141

[44] PrinceR.L., LarkinsR.G., AlfordF.P.. The effect of acetylsalicylic acid on plasma glucose and the response of glucose regulatory hormones to intravenous glucose and arginine in insulin treated diabetics and normal subjects. Metab Clin Exp, 1981, 30(3): 293-298

[45] RidkerP.M., CookN.R., LeeI.M., et al.. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med, 2005, 352(13): 1293-1304

[46] SaccoM., PellegriniF., RoncaglioniM.C., et al.. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care, 2003, 26(12): 3264-3272

[47] HeJ.R., NiA.M., ZhangH.G.. Effect of captopril with aspirin on inceptive diabetic nephropathy. J Lanzhou Med Col (Chinese), 1995, 25(2): 31-33

[48] ZhangW., ChenY., LiuS., et al.. The effect of aspirin to type 2 diabetic heart rate variability. J Shenyang Med Col (Chinese), 2002, 4(1): 28-30

[49] LiW.M., XiongY.G., WangZ., et al.. Clinical study on the prevention and treatment of NIDDM retinopathy with small dose aspirin. J Pharmac Prac (Chinese), 1998, 16(6): 335-337

[50] LiR.L., XieC.C.. Analysis of 30 diabetic patients treated with aspirin. J Handan Med Col (Chinese), 2000, 13(4): 333

[51] LinL., ZhaoY.L., ShiF.J.. Dynamic changes of IL-8 and CRP in senile type 2 diabetic patients after adminsteration of aspirin. China Trop Med (Chinese), 2006, 6(4): 645-646

[52] WangL., ZhaoX.W., ZhangY., et al.. Serum C-reactive protein levels in type 2 diabetes patients and effects of aspirin on C-reactive protein. J Shanxi Med Univ (Chinese), 2005, 36(6): 721-723

[53] DongA.W.. Clinical analysis of decrease of HbA1c level by aspirin on 55 diabetic patients. Pract Clin Med (Chinese), 2002, 3(2): 131-132

[54] JiangX.Z., GuZ., ZhouB., et al.. Effects of aspirin on inflammatory factors of type 2 diabetes mellitus patients. Chin J New Drugs Clin Rem (Chinese), 2009, 28(4): 297-300

[55] LuS.Q.. Clinical effectiveness of enalapril and aspirin on incipient diabetic nephropathy. Guangxi Med J (Chinese), 2004, 26(2): 186-188

[56] ChenN.H., ZhouP., HeR.H., et al.. Relationship between change in content of platelet α-granule membrane protein and nephropathy in type 2 diabetic patients. Jiangsu Med J (Chinese), 2000, 26(9): 687-689

[57] FieldJ.B., BoyleC., RemerA.. Effect of salicylate infusion on plasma-insulin and glucose tolerance in healthy persons and mild diabetics. Lancet, 1967, 1(7501): 1191-1194

[58] RobertsonR.P., ChenM.. A role for prostaglandin E in defective insulin secretion and carbohydrate intolerance in diabetes mellitus. J Clin Invest, 1977, 60(3): 747-753

[59] Bratusch-MarrainP.R., VierhapperH., KomjatiM., et al.. Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man. Diabetologia, 1985, 28(9): 671-676

[60] MicossiP., PontiroliA.E., BaronS.H., et al.. Aspirin stimulates insulin and glucagon secretion and increases glucose tolerance in normal and diabetic subjects. Diabetes, 1978, 27(12): 1196-1204

[61] MubarakA.A.. Is low-dose aspirin a useful adjuvant therapy in the treatment of NIDDM?. Diabet Med, 1997, 14(5): 405-406

[62] StrakoschC.R., JefferysD.B., KeenH.. Blockade of chlorpropamide alcohol flush by aspirin. Lancet, 1980, 1(8165): 394-396

[63] SkrhaJ., HilgertovaJ., SvacinaS., et al.. Insulin receptors and glucose homeostasis in type 2 diabetics influenced by acetyl-salicylic acid treatment. Exp Clin Endocrinol, 1988, 92(1): 119-122

[64] HundalR.S., PetersenK.F., MayersonA.B., et al.. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest, 2002, 109(10): 1321-1326

[65] HopperA.H., TindallH., DaviesJ.A.. Effect of aspirin on glucose tolerance and insulin levels in patients with type 2 diabetes mellitus. Thromb Haemost, 1985, 54(4): 895

[66] VierhapperH., Bratusch-MarrainP., WaldhauslW., et al.. Increased secretion of insulin but unchanged secretion of growth hormone in hyperglycaemic type II diabetics treated with acetyl-salicylic acid. Clin Endocrinol (Oxf), 1983, 18(6): 613-619

[67] TornvallG., AllgenL.G.. Acute effects of acetylsalicylic acid on blood glucose and insulin in non-insulin dependent diabetes. Acta Endocrinol Suppl (Copenh), 1980, 239: 6-8

[68] TianH.M., LiangJ.Z., LiY., et al.. Effects of aspirin on plasma glucose and platelet for diabetic patients. Sichuan Med J (Chinese), 1989, 10(4): 206-207

[69] YuJ., WanJ., PanZ.Q.. Effects of fluvastatin and aspirin on C-reactive protein for old people with coronary heart disease and type 2 diabetes. Prac Geriat J (Chinese), 2008, 22(3): 232-234

[70] BrassE.P., HalterJ.B., EnsinckJ.W., et al.. Effect of sodium salicylate on hormonal responses to hypoglycaemia in type II diabetics. Clin Endocrinol (Oxf), 1984, 21(6): 649-655

[71] ChenM., RobertsonR.P.. Restoration of the acute insulin response by sodium salicylate. A glucose dose-related phenomenon. Diabetes, 1978, 27(7): 750-756

[72] GilgoreS.G., DrewW.L., RuppJ.J.. The effect of salicylate on plasma nonesterified fatty acids. Am J Med Sci, 1963, 245: 456-458

[73] McRaeJ.R., MetzS.A., RobertsonR.P.. A role for endogenous prostaglandins in defective glucose potentiation of nonglucose insulin secretagogues in diabetics. Metabolism, 1981, 30(11): 1065-1075

[74] VaneJ.R.. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol, 1971, 231(25): 232-235

[75] WuK.K.. Aspirin and salicylate: An old remedy with a new twist. Circulation, 2000, 102(17): 2022-2023

[76] YinM.J., YamamotoY., GaynorR.B.. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature, 1998, 396(6706): 77-80

[77] KoppE., GhoshS.. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science, 1994, 265(5174): 956-959

[78] YuanM., KonstantopoulosN., LeeJ., et al.. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science, 2001, 293(5535): 1673-1677

[79] PierceJ.W., ReadM.A., DingH., et al.. Salicylates inhibit I kappa B-alpha phosphorylation, endothelial-leukocyte adhesion molecule expression, and neutrophil transmigration. J Immunol, 1996, 156(10): 3961-3969

[80] XiaoC., GiaccaA., LewisG.F.. The effect of high-dose sodium salicylate on chronically elevated plasma non-esterified fatty acid-induced insulin resistance and beta cell dysfunction. Am J Physiol Endocrinol Metab, 2009, 297(5): E1205-1211